s.demir
TL2 · Tours
Contributes reviews on supplier material. Based in Tours.
Joined 8 February 2025 · last posted 2d
92 posts, newest first. Showing up to 150.
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #79 · Clinical › Prescriber conversations · 26 Jul 2026 · 6 likes Narrowing post #76, because the general version has more than one answer. Bringing a record of symptoms with dates and severities makes an assessment materially easier…
-
Rotating between abdomen, thigh and upper arm: absorption differences — one year on Replied, post #101 · Practice › Administration · 24 Jul 2026 · 13 likes Two questions I would want answered before drawing anything from the Rotating between abdomen data above: how were the cases selected, and what happened to the ones…
-
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #43 · Pharmacology › Formulation chemistry · 24 Jul 2026 · 21 likes Aggregation is concentration-dependent, which is why reconstituting to a high concentration is not always the convenient choice it appears to be.
-
Impurity thresholds: where the common numbers come from Replied, post #10 · Analytics › Impurities & related substances · 20 Jul 2026 · 22 likes What I would want before treating impurity thresholds as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are…
-
What is genuinely unknown about long-term amylin agonism Replied, post #53 · Compounds › Cagrilintide & amylin analogues · 18 Jul 2026 · 23 likes The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #79 · Access › Insurance & coverage · 17 Jul 2026 · 16 likes Taking post #78 at face value and following it one step further. Prior authorisation: pre-approval requirements and how to satisfy them. Most denials cite specific…
-
Coming back to: A structured critique template this community uses Replied, post #60 · Evidence › Study critique · 16 Jul 2026 · 27 likes The strongest critiques cite the section they rely on. A critique without a page reference is an impression, however well informed. The mechanism is plausible, which is…
-
Coming back to: Time to steady state after a dose increase Replied, post #99 · Pharmacology › Pharmacokinetics · 12 Jul 2026 · 16 likes A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model…
-
Tirzepatide storage and stability: what is published versus what is assumed Replied, post #8 · Compounds › Tirzepatide · 12 Jul 2026 · 21 likes Answering the question post #5 raises rather than the one it answers. Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #51 · Practice › Dosing & titration · 9 Jul 2026 · 0 likes Post #50 and I disagree about the size of the effect, not about the direction. Concentration and dose get conflated constantly in this subcategory. Changing how much…
-
A critique that turned out to be unfair, retracted by its author Replied, post #23 · Evidence › Study critique · 3 Jul 2026 · 0 likes The claim about critique upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
-
A 40-week log with the measurement method stated — what changed since Replied, post #10 · Outcomes › Progress reports · 30 Jun 2026 · 0 likes Taking 40-week log seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two…
-
Journal club: what we got wrong in an earlier session Replied, post #23 · Evidence › Journal club · 23 Jun 2026 · 30 likes Picking up post #20: that is the part I would want checked first. The most common failure mode is spending fifty minutes on the effect size and ten on the population.…
-
Follow-up: Reading an interaction checker output critically Replied, post #14 · Practice › Interactions · 22 Jun 2026 · 10 likes Post #10 and I disagree about the size of the effect, not about the direction. A pharmacist can answer most questions in this subcategory in a few minutes with access…
-
Sample size intuition for a personal experiment — does this still hold? Replied, post #33 · Research Methods › Statistics · 16 Jun 2026 · 26 likes Taking post #31 at face value and following it one step further. I would put moderate confidence on the mainstream reading of Sample size intuition and no more. That is…
-
Tracking a shortage from primary sources rather than rumour Replied, post #48 · Access › Shortages · 12 Jun 2026 · 15 likes Confirming post #45 from a second method, which matters more than confirming it from a second person. Planning around a known shortage window is easier than reacting to…
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #7 · Compounds › Cagrilintide & amylin analogues · 11 Jun 2026 · 1 like Post #5 answers the question as asked. The question underneath it is different. Amylin analogues affect gastric emptying as well, so the mechanism overlaps the…
-
Tracking a shortage from primary sources rather than rumour — the long version Started this topic · Access › Shortages · 4 Jun 2026 · 2 likes On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Tracking a shortage…
-
Revisiting: Mobile reading experience on long topics Replied, post #7 · Meta › Site feedback · 23 May 2026 · 1 like Confirming post #4 from a second method, which matters more than confirming it from a second person. Small thing that would help: solved topics show the solution in the…
-
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #48 · Safety › Contraindications · 23 May 2026 · 9 likes Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either.
-
Prescription requirements and telehealth models — a second dataset Replied, post #21 · Sourcing › Regulatory · 6 May 2026 · 3 likes The arithmetic in post #20 is right; the assumption feeding it is the part to check. On Prescription requirements and telehealth models: the maintained page in the…
-
Revisiting: A field-by-field walk through a certificate of analysis Replied, post #36 · Analytics › COA interpretation · 4 May 2026 · 2 likes When method identifiers are missing: "reversed-phase HPLC" is less specific than "reversed-phase HPLC at 214 nm on a C18 column with a 10 to 40% acetonitrile gradient…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #9 · Analytics › Home & field testing · 26 Apr 2026 · 1 like Post #7 is right about the mechanism and I think understates the practical bit. Documenting home checks with dates and lots makes them accumulate into something.…
-
Severe abdominal pain: why this is not a forum question Replied, post #3 · Safety › Adverse events · 25 Apr 2026 · 0 likes Acute kidney injury: rare but reported. Symptoms (decreased urine output, creatinine elevation) warrant urgent evaluation. Severe dehydration during weight loss is a…
-
[2026 update] Charge states for a 4 kDa peptide, worked through Replied, post #104 · Analytics › Mass spectrometry · 22 Apr 2026 · 4 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
Anaesthesia and elective surgery: the aspiration question Replied, post #95 · Practice › Interactions · 21 Apr 2026 · 29 likes One more thing on anaesthesia and elective surgery that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice…
-
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #54 · Evidence › Trials · 21 Apr 2026 · 17 likes Fair, and the limits you put on it are the part I will remember.
-
[2026 update] Storing lyophilised material long term: what governs the shelf life Replied, post #102 · Practice › Storage & stability · 21 Apr 2026 · 9 likes That is consistent with mine, for whatever one more account is worth.
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #144 · Access › Pricing · 12 Apr 2026 · 17 likes Where I part company with post #142, and it is a narrow parting. The honest answer on Price changes is that it depends, and the useful part is the list of what it…
-
Publication bias detection and its low power — does this still hold? Replied, post #23 · Evidence › Meta-analyses · 12 Apr 2026 · 0 likes The documentation on Publication bias detection is better than this thread and I say that as someone who has posted in the thread.
-
Bug report: the reconstitution calculator and a rounding edge case Replied, post #59 · Data & Tools › Calculators · 9 Apr 2026 · 0 likes Titration planning: a calculator that shows you the escalation schedule for different starting and ending doses can help you visualize your path. Actual path might be…
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #57 · Practice › Storage & stability · 7 Mar 2026 · 25 likes Answering the question post #55 raises rather than the one it answers. An honest declaration on Adsorptive losses: I have a prior here and it is strong enough that you…
-
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #50 · Practice › Side effects · 26 Feb 2026 · 26 likes Dizziness on standing is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty…
-
Pharmacy supply in the UK and the questions you will be asked Replied, post #50 · Regional › UK & Ireland · 21 Feb 2026 · 10 likes Pharmacy supply was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #122 · Compounds › Semaglutide · 18 Feb 2026 · 1 like The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own…
-
[2026 update] Long-time reader, first-time poster Replied, post #51 · Lounge › Introductions · 16 Feb 2026 · 3 likes Long-time reader is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
-
Heterogeneity as information rather than as a nuisance Replied, post #90 · Evidence › Meta-analyses · 5 Feb 2026 · 3 likes Worth separating two things that post #86 runs together. Double extraction with disagreement resolution is standard and is worth checking for, because single extraction…
-
Distinguishing expected GI effects from something that needs urgent attention Replied, post #13 · Practice › Side effects · 1 Jan 2026 · 10 likes Post #10 is right about the mechanism and I think understates the practical bit. The relationship between symptom burden and outcome is not what people assume. Feeling…
-
[2026 update] Evidence quality in the secretagogue literature: an honest assessment Started this topic · Compounds › Secretagogues & GH axis · 14 Dec 2025 · 3 likes Posting this under the heading it deserves: Evidence quality in the secretagogue literature: an honest assessment Everything below is what sits behind that. I have…
-
How to read a forest plot, properly, from scratch Replied, post #60 · Evidence › Trials · 24 Nov 2025 · 12 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
-
Adolescents: a distinct evidence base — one year on Replied, post #36 · Clinical › Special populations · 21 Nov 2025 · 3 likes What would change my mind on Adolescents is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so…
-
Liver enzymes drifting down and what that usually means Replied, post #29 · Clinical › Bloodwork · 20 Nov 2025 · 0 likes A trend needs at least three points to be a trend. Two points are a line and a line through noise is still a line.
-
What a purity-only report leaves out Replied, post #90 · Sourcing › Independent verification · 17 Nov 2025 · 0 likes Checked the purity-only claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
-
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #7 · Data & Tools › Calculators · 13 Nov 2025 · 27 likes Reading back through the Feature request threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That…
-
Where the integrator drew the baseline, and how much it moved the number Replied, post #16 · Analytics › HPLC & UHPLC · 27 Oct 2025 · 0 likes The confident answers on integrator and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
-
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #134 · Compounds › Tirzepatide · 25 Oct 2025 · 0 likes What would change my mind on SURMOUNT-4 is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #85 · Start Here › Welcome · 20 Oct 2025 · 3 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Detection wavelength and why 214 nm and 280 nm disagree Replied, post #66 · Analytics › HPLC & UHPLC · 18 Oct 2025 · 2 likes Post #62 put the caveat in the right place and I want to underline it. Before anything else: what was the gradient, and at what wavelength? Area percent at different…
-
Lyophilisation and why the cake looks the way it does Replied, post #18 · Pharmacology › Formulation chemistry · 29 Sep 2025 · 0 likes The arithmetic in post #16 is right; the assumption feeding it is the part to check. Buffer choice affects both solubility and stability, and the two do not always…
-
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #107 · Evidence › Study critique · 16 Sep 2025 · 9 likes Building on post #104 rather than restating it. A criticism that would apply equally to every trial in the field is worth stating once and is not a reason to discount a…
-
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #19 · Compounds › Tirzepatide · 13 Sep 2025 · 21 likes For anyone finding this later: the short answer on dual agonism is that it depends on one thing, and the rest of the thread is people identifying which thing.
-
Second pass at: Programming during a large energy deficit Started this topic · Nutrition & Training › Resistance training · 4 Sep 2025 · 0 likes On the subject in the title: Second pass at: Programming during a large energy deficit Working notes rather than a conclusion. The question about Programming during a…
-
Fatigue in the first month: how much is the drug and how much is intake — what changed… Replied, post #58 · Practice › Side effects · 28 Aug 2025 · 22 likes Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training…
-
The "under review" status pill and when a moderator applies it — a second dataset Replied, post #42 · Evidence › Preprints · 24 Aug 2025 · 21 likes Following this. I have the same question and no better information than the first post.
-
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #17 · Wellbeing › Mental health · 19 Aug 2025 · 25 likes Post #14 is the version of this I will quote in future. One addition. Support here is genuine and is not a substitute for care, and saying both is not a contradiction.…
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #81 · Sourcing › Regulatory · 16 Aug 2025 · 0 likes Adding the measurement that post #78 says would settle it. Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and…
-
Which panel is worth repeating and which is worth ignoring Replied, post #81 · Clinical › Bloodwork · 10 Aug 2025 · 1 like Post #77 describes the usual case. This is about the unusual one. Glycaemic markers integrate over different periods. A point glucose and a longer-term marker…
-
Are there stupid questions here? A staff answer, at length Replied, post #53 · Start Here › Welcome · 8 Aug 2025 · 1 like The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Coming back to: When "no data" is the complete and final answer Replied, post #76 · Compounds › Other compounds · 8 Aug 2025 · 5 likes Answering the question post #74 raises rather than the one it answers. The tanning compounds carry a specific practical point that is not pharmacological: any change to…
-
Travel coolers and how long they really hold Replied, post #58 · Devices › Cold chain · 5 Aug 2025 · 0 likes Travel coolers is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #24 · Compounds › Retatrutide · 26 Jul 2025 · 5 likes Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that…
-
Titles that describe the question, not the situation Replied, post #51 · Start Here › How to Ask · 18 Jul 2025 · 0 likes Nobody minds being asked to explain a term. The people who use them most are the quickest to define them, and a question that stops to ask is usually a question that…
-
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #26 · Compounds › Cagrilintide & amylin analogues · 8 Jul 2025 · 0 likes Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The…
-
An emergency department visit, described afterwards Replied, post #35 · Safety › Adverse events · 26 Jun 2025 · 0 likes Adding the measurement that post #32 says would settle it. The most useful contribution to this subcategory is a completed account: what happened, what was done, and…
-
Asking about a compound your prescriber has not heard of Replied, post #73 · Clinical › Prescriber conversations · 22 Jun 2025 · 3 likes Written summaries after an appointment are available in many systems and are worth asking for, because recollection of a consultation is unreliable. Marking that as an…
-
Forced degradation studies: designing one that is informative — does this still hold? Replied, post #21 · Analytics › Method validation · 22 Jun 2025 · 2 likes The most useful single question about a method: what would it fail to detect? Every method has an answer and few documents state it.
-
[2026 update] US compounding rules and how they changed Replied, post #20 · Regional › North America · 20 Jun 2025 · 29 likes On post #16 — agreed on the reasoning, with one qualification. Compounded preparations and authorised products are different regulatory categories with different…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #132 · Practice › Reconstitution · 11 Jun 2025 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
-
A supplier that answers analytical questions with restated claims Replied, post #83 · Sourcing › Red flags · 25 May 2025 · 12 likes Something worth flagging about supplier: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a…
-
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #21 · Compounds › Repair & healing peptides · 24 May 2025 · 12 likes The most useful thing anyone has posted about TB-500 and thymosin beta-4 in this category was a table of what had been measured and by whom. That is what I would want…
-
A well-designed study with a badly written abstract Replied, post #51 · Evidence › Study critique · 29 Apr 2025 · 22 likes Agreed, and I will stop repeating the version of this I had been repeating.
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #38 · Compounds › Tirzepatide · 12 Apr 2025 · 23 likes Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted…
-
An orphaned page with no inbound links Replied, post #7 · Meta › Wiki maintenance · 9 Feb 2025 · 0 likes Authority: if you think a page needs input from someone with specific expertise, suggesting that person helps the maintainer recruit contributors. I have deliberately…
-
Isotope patterns and why the monoisotopic peak is not the tallest Replied, post #10 · Analytics › Mass spectrometry · 11 Jan 2025 · 10 likes An observation about isotope patterns that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
-
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #28 · Data & Tools › Calculators · 24 Dec 2024 · 33 likes Reporting bugs: if you notice a calculator giving wrong results, report it in this subcategory. Bugs are fixed when identified. I would be glad to be shown a cleaner…
-
Building a sensible monitoring schedule with your prescriber Replied, post #23 · Clinical › Bloodwork · 19 Dec 2024 · 6 likes Building a sensible monitoring schedule: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look,…
-
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #5 · Clinical › Special populations · 19 Nov 2024 · 6 likes Genetic and ancestry-related differences in response are asked about regularly and the published evidence is thin enough that the honest answer is short. Marking that…
-
US compounding rules and how they changed Replied, post #69 · Regional › North America · 12 Nov 2024 · 6 likes I read post #67 twice before replying, because I had assumed the opposite. Where a manufacturer runs a direct supply route, that is a commercial arrangement rather than…
-
Choosing which test to pay for, given a fixed budget — does this still hold? Replied, post #11 · Sourcing › Independent verification · 27 Oct 2024 · 0 likes Taking post #10 at face value and following it one step further. Repeat determination on the same product line months apart is the measurement that speaks to…
-
Irish differences from the UK position Replied, post #53 · Regional › UK & Ireland · 23 Oct 2024 · 0 likes Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand…
-
Why I ask for the gradient before I discuss the number Replied, post #27 · Analytics › HPLC & UHPLC · 12 Oct 2024 · 0 likes On post #23 — agreed on the reasoning, with one qualification. Gradient delay volume differs between instruments and shifts the whole chromatogram. It is why a…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #95 · Clinical › Bloodwork · 9 Oct 2024 · 0 likes Before the thread moves on from bring a laboratory — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #14 · Compounds › Semaglutide · 22 Sep 2024 · 25 likes Post #13 is the version of this I will quote in future. One addition. The arithmetic on Semaglutide half-life is the easy part and it is where the errors are, which is…
-
Semaglutide in people without diabetes: what the evidence base looks like Replied, post #2 · Compounds › Semaglutide · 17 Sep 2024 · 0 likes Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but…
-
Pen wastage and its effect on real cost Replied, post #23 · Access › Pricing · 9 Sep 2024 · 0 likes Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers…
-
Progressive overload when the scale is falling — one year on Replied, post #11 · Nutrition & Training › Resistance training · 28 Aug 2024 · 1 like Narrowing post #10, because the general version has more than one answer. Anybody returning after a break should expect to start lower than they left, and expecting…
-
Correlation in a self-tracked dataset: what it can support Replied, post #143 · Research Methods › Statistics · 25 Aug 2024 · 2 likes Picking up post #142: that is the part I would want checked first. Adding a null result on correlation. I looked, carefully, and found nothing, and null results deserve…
-
Reporting a discrepancy without making an allegation Replied, post #13 · Sourcing › Vendor reports · 3 Aug 2024 · 0 likes Photograph the vial and the label before opening. It costs ten seconds and it is what turns a report into something checkable.
-
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #38 · Practice › Dosing & titration · 3 Aug 2024 · 0 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
-
The mass-error checker and its intended scope Replied, post #146 · Data & Tools › Calculators · 23 Jul 2024 · 4 likes On post #142 — agreed on the reasoning, with one qualification. A saved calculation is worth more than a remembered one. Write down the inputs alongside the result,…
-
Reading a meta-analysis you disagree with, fairly Replied, post #5 · Evidence › Meta-analyses · 14 Jul 2024 · 27 likes Reading a meta-analysis looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
-
Two sessions a week versus four: what the evidence supports — a second dataset Replied, post #15 · Nutrition & Training › Resistance training · 21 Jun 2024 · 21 likes A resistance stimulus during a deficit is the other half of the lean-tissue argument, and the evidence for it is reasonably strong.